HI-Bio™ Receives Orphan Drug Designation for Felzartamab Targeted Therapy
HI-Bio™ has received Orphan Drug Designation from the FDA for felzartamab, a targeted therapy for antibody-mediated rejection in kidney transplant recipients. This designation is a significant milestone in addressing the critical unmet medical need for AMR, with potential breakthrough implications. The Orphan Drug Designation qualifies HI-Bio for certain development incentives, expected to accelerate the development of felzartamab and enhance the company’s ability to bring this innovative therapy to patients in need.
Genetically Modified Pigs Offer Hope for Organ Transplantation
Scientists are making groundbreaking strides in the field of organ transplantation, offering hope for the thousands of patients awaiting life-saving procedures. The latest development involves genetically modified pigs, which could potentially put an end to the shortage of organs for transplants. Researchers are optimistic about the potential of gene-edited animals to serve as a new source of organs for transplantation, marking a significant advancement in the field of medical science.